

STUDIENLISTE Juni 2020

BASEC-Nr.	Atopische Dermatitis		Kontaktdaten	Status
2018-00489	BREEZE-AD4 / I4V-MC-JAIN	A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination with Topical Corticosteroids in Adult Patients with Moderate-to-Severe Atopic Dermatitis Who Have Experienced Failure to Cyclosporine or Are Intolerant to, or Have Contraindication to, Cyclosporine	Prof. Antonio Cozzio Antonio.cozzio@kssg.ch Tanja Zeller Tanja.zeller@kssg.ch	Kein Einschluss mehr möglich
BASEC-Nr.	Melanom		Kontaktdaten	Status
2018-01154	Keynote 716 / MK3475-716	Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-Blind Phase 3 Study	Prof. Lukas Flatz Lukas.flatz@kssg.ch Tanja Zeller Tanja.zeller@kssg.ch	Einschluss möglich
BASEC-Nr.	Mycosis Fungoides (MF) / Sézary Syndrome (SS)		Kontaktdaten	Status
2016-01795	RESMAIN study/ 4SC-201-6-2015	A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy	Prof. Antonio Cozzio Antonio.cozzio@kssg.ch Tanja Zeller Tanja.zeller@kssg.ch	Einschluss möglich
BASEC-Nr.	Psoriasis		Kontaktdaten	Status
2017-02155	Aprescalp / DER-USZ-AAN-021	A phase 4 multicenter, randomized, placebo-controlled study evaluating the effect of Apremilast on pruritus and quality of life of patients with moderate-to-severe scalp Psoriasis	Prof. Antonio Cozzio Antonio.cozzio@kssg.ch Tanja Zeller Tanja.zeller@kssg.ch	Einschluss möglich
2018-02295	EMBRACE / CC-10004-PSOR-020	A Phase 4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Of The Impact Of Apremilast (CC-10004) On Quality Of Life, Efficacy, And Safety In Subjects With Manifestations Of Plaque Psoriasis And Impaired Quality of Life	Prof. Antonio Cozzio Antonio.cozzio@kssg.ch Tanja Zeller Tanja.zeller@kssg.ch	Einschluss möglich
2016-00135	Secukinumab/AI N457 / CAIN457A2310	A randomized, double-blind, placebo- and active controlled multicentre trial to demonstrate efficacy of subcutaneous secukinumab compared to placebo and entanercept (in a single-blind arm) after twelve weeks of treatment, and to assess the safety, tolerability, and long-term efficacy in subjects from 6 to less	Prof. Antonio Cozzio Antonio.cozzio@kssg.ch Tanja Zeller Tanja.zeller@kssg.ch	Kein Einschluss mehr möglich

		than 18 years of age with severe chronic plaque psoriasis		
2016-01618	SERENA / CAIN457A3403	Long-term observational, prospective study to collect in a real life setting data on the retention, efficiency of secukinumab in adult patients with moderate to severe plaque psoriasis, psoriatic arthritis or ankylosing spondylitis	Prof. Antonio Cozzio Antonio.cozzio@kssg.ch Tanja Zeller Tanja.zeller@kssg.ch	Kein Einschluss mehr möglich
2016-01782	SDNTT	Swiss Dermatology Network for Targeted Therapies (SDNTT) Objective Long-Term Benefits and Safety of Systemic Psoriasis Therapy: Swiss Registry on the Treatment of Psoriasis with Biologics and Systemic Therapeutics based on PsoBest German Registry and in operational cooperation with CVderm in Hamburg	Prof. Antonio Cozzio Antonio.cozzio@kssg.ch Tanja Zeller Tanja.zeller@kssg.ch	Einschluss möglich

BASEC-Nr.	Urtikaria		Kontaktdaten	Status
2018-00542	QGE031/ Ligelizumab / QGE031C2202	A multicentre, randomized, double-blind, placebo-controlled phase 2b dose-finding study to investigate the efficacy and safety of ligelizumab (QGE031) in adolescent patients with Chronic Spontaneous Urticaria (CSU)	Prof. Antonio Cozzio Antonio.cozzio@kssg.ch Tanja Zeller Tanja.zeller@kssg.ch	Kein Einschluss mehr möglich

Alle Informationen zur Klinischen Forschung der Klinik für Dermatologie, Venerologie und Allergologie finden Sie unter: <https://www.kssg.ch/dermatologie/klinische-forschung>